Abstracts tagged "SLE"

Abstract Number: 2722 • 2014 ACR/ARHP Annual Meeting
Rapamycin Corrects GATA-3 Deficiency in Lupus Treg
Hiroshi Kato¹ and Andras Perl², ¹Internal Medicine, Division of Rheumatology, SUNY Upstate Medical University, Syracuse, NY, ²Dept of Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: As demonstrated by the negative correlation between Treg frequency or suppressive function and SLE disease activity index score, it is tempting to speculate that…
Abstract Number: 2112 • 2014 ACR/ARHP Annual Meeting
Patterns of Medication Use Before, During, and After Pregnancy Among Women with Systematic Lupus Erythematosus: A Population-Based Study
Mary De Vera¹, Eric C. Sayre², Corisande Baldwin³, Jessica Galo⁴ and J. Antonio Avina-Zubieta⁵, ¹University of British Columbia Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁴Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately affects women during childbearing years. Given the limited data on perinatal medication use among patients, our objective was…
Abstract Number: 1632 • 2014 ACR/ARHP Annual Meeting
Is Liopxin A4 a Biomarker for Systemic Lupus Erythematosus?
Manal Sedky Abdou¹, Dina Effat², Lamiaa Mansour³, Mona mohsen Abdul Salam³ and Noha abd El Baky⁴, ¹rheumatology and rehabilitation kasr el aini hospital, faculty of medicin, cairo university, cairo, Egypt, ²rheumatology and rehabilitation, faculty of medicin, cairo university, giza, Egypt, ³clinical and chemical pathology, faculty of medicin, cairo university, cairo, Egypt, ⁴rheumatology and rehabilitation, faculty of medicin, cairo university, cairo, Egypt
Background/Purpose : Systemic lupus erythematosus (SLE) is characterized by autoantibody production and immune complex deposition which trigger both a local and systemic inflammatory response. The…
Abstract Number: 859 • 2014 ACR/ARHP Annual Meeting
TGF-β3-Producing CD4⁺CD25^–LAG3⁺ Regulatory T Cells Control B Cell Responses
Tomohisa Okamura¹, Kaoru Morita¹, Mariko Inoue¹, Toshihiko Komai¹, Yukiko Iwasaki¹, Shuji Sumitomo¹, Shinichiro Nakachi¹, Hirofumi Shoda², Keishi Fujio² and Kazuhiko Yamamoto¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan, ²Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production and associated with a wide range of clinical manifestations. Recent case-control association…
Abstract Number: 636 • 2014 ACR/ARHP Annual Meeting
Liposomal-Glucocorticoids: A Novel Approach to the Therapy of SLE
Yaakov Naparstek¹, Eli Moallem², Rina Ulmansky³, Erez Koren³ and Yechezkel Barenholz³, ¹Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, Israel, ²Dept. of Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, Israel, ³Hadassah - Hebrew University Medical Center, Jerusalem, Israel
Background/Purpose Glucocorticoids (GCs) have been known for years to be the most effective therapy in SLE. Their use is however limited by the need of…
Abstract Number: 2696 • 2014 ACR/ARHP Annual Meeting
Relationship Between Soluble sCD23 and B Cell Activation Factor in Patients with Systemic Lupus Erythematosus before and after Rituximab
Laura Heretiu^1,2, Maria J. Leandro³, Venkat Reddy⁴, David A. Isenberg⁵ and Geraldine Cambridge³, ¹Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ²Rheumatology and Internal Medicine, 'Sf. Maria' Clinical Hospital, Bucharest, Romania, ³Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ⁵Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose CD23 is the low-affinity receptor for IgE (FceRII). The soluble form, sCD23 is released into the circulation and in vitro this is consistent with…
Abstract Number: 2049 • 2014 ACR/ARHP Annual Meeting
Fatigue Is a Risk Factor for Subsequent Functional Decline in SLE
Patricia P. Katz¹, Laura Trupin¹, Jennifer Barton¹, Gabriela Schmajuk¹, Mary Margaretten² and Edward H. Yelin³, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³Arthritis Research Group, University of California, San Francisco, San Francisco, CA
Background/Purpose: In geriatrics, fatigue has been shown to be a harbinger of future functional decline. Fatigue is associated with poor function in systemic lupus erythematosus…
Abstract Number: 1628 • 2014 ACR/ARHP Annual Meeting
Upregulation of Myxovirus Resistance Protein 1 in Patients with Neuropsychiatric Systemic Lupus Erythematosus
Yuka Shimizu, Shinsuke Yasuda, Takashi Kurita, Sanae Shimamura, Ikuma Nakagawa, Atsushi Noguchi, Haruki Shida, Toshiyuki Watanabe, Michihito Kono, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Nervous system disease is one of the most common manifestations in patients with systemic lupus erythematosus (SLE) that significantly affects morbidity and mortality. Due…
Abstract Number: 719 • 2014 ACR/ARHP Annual Meeting
Target Modulation of a Type I Interferon (IFN) Gene Signature with Sifalimumab or Anifrolumab in Systemic Lupus Erythematosus (SLE) Patients in Two Open Label Phase 2 Japanese Trials
Chris Morehouse¹, Linda Chang², Liangwei Wang³, Philip Brohawn¹, Shinya Ueda⁴, Gabor Illei⁵, Warren Greth³, Stephen Yoo⁶, Lorin Roskos⁷, Yihong Yao⁸, Gabriel Robbie⁹ and Brandon W. Higgs¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Translational Sciences, MedImmune, Hayward, CA, ³MedImmune, LLC, Gaithersburg, MD, ⁴PK, Astrazeneca, Osaka, Japan, ⁵Clinical Development, Medimmune, Gaithersburg, MD, ⁶Clinical Development, MedImmune, LLC, Gaithersburg, MD, ⁷One MedImmune Way, Medimmune, Gaithersburg, MD, ⁸Translational Sciences, MedImmune, Gaithersburg, MD, ⁹Clinical Pharmacology and DMPK, MedImmune, Gaithersburg, MD
Background/Purpose The pharmacokinetic (PK) and pharmacodynamic (PD) effects of two investigational monoclonal antibodies inhibiting type I IFN signaling - sifalimumab or anifrolumab, specific for IFN-α…
Abstract Number: 238 • 2014 ACR/ARHP Annual Meeting
RANKL and OPG Gene Polymorphisms: Association with Vertebral Fractures and Bone Mineral Density in Premenopausal Systemic Lupus Erythematosus
Alessandra C. Bonfa¹, Luciana P.C. Seguro², Valéria Caparbo³, Eloisa Bonfa³ and Rosa M R Pereira³, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose To evaluate single nucleotide polymorphisms (SNPs) of the receptor activator of NF-κB ligand (RANKL), RANK and osteoprotegerin (OPG) genes in premenopausal systemic lupus erythematosus…
Abstract Number: 2693 • 2014 ACR/ARHP Annual Meeting
Hyporesponsiveness to TLR9 in Term of Cytokines Production By B Cells in SLE-Patients
Julia Sieber¹, Capucine Daridon¹, Sarah J. Fleischer¹, Vanessa Fleischer¹, Falk Hiepe¹, Tobias Alexander², Guido Heine³, Gerd Burmester⁴, Simon Fillatreau⁵ and Thomas Dörner¹, ¹Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology/German Rheumatism Research Center (DRFZ), Berlin, Germany, ²Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology/German Rheumatism Research Center (DRFZ), Berlin, Germany, ³Charité University Medicine, Dept. Dermatology, Venerology and Allergology, Berlin, Germany, ⁴Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology, Berlin, Germany, ⁵German Rheumatism Research Center (DRFZ), Berlin, Germany
Background/Purpose The role of B cells in immunity has been mainly related to the generation of antibodies and formation of immune complexes. However, B cells…
Abstract Number: 1980 • 2014 ACR/ARHP Annual Meeting
Thrombospondin-1 Is Elevetad in the Plasma of Patients with Antiphospholipid Syndrome and Is Correlated with Soluble Fas Ligand and Free Active TGF-B levels
Markos Patsouras¹, Marina Sikara², Athanasios G. Tzioufas² and Panayiotis Vlachoyiannopoulos², ¹PATHOPHYSIOLOGY DEPARTMENT, UNIVERSITY OF ATHENS, School of Medicine, National University of Athens, Athens, Greece, ²Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose Antiphospholipid syndrome (APS) is an acquired thombophillia characterized by recurrent thromboembolism and pregnancy morbidity. Thrombospondin (TSP-1) is a matricellular glycoprotein with antiangiogenic and proapoptotic…
Abstract Number: 1616 • 2014 ACR/ARHP Annual Meeting
Functional Profiling of PBMC from SLE Patients Versus Healthy Controls Identifies Subgroups with Disease-Associated Dysfunctional Signaling
Rachael Hawtin¹, Wouter Korver², Erik Evensen², Diane Longo², Drew Hotson², Nikil Wale², Andy Conroy², Alessandra Cesano², Barbara Mittleman², Shirley Tu², Matt Westfall², Tsung Lin³, Vik Rao⁴, Elena Peeva⁵, Stephen Benoit⁵, Martin Hodge³, James D. Clark³, Jean-Baptiste Telliez³ and Aaron R. Winkler⁴, ¹Nodality Inc., South San Francisco, CA, ²Nodality, Inc., South San Francisco, CA, ³Immunoscience, Pfizer Biotherapeutics Research and Development, Cambridge, MA, ⁴Inflammation and Remodeling, Pfizer Biotherapeutics Research and Development, Cambridge, MA, ⁵Precision Medicine, Pfizer Biotherapeutics Research and Development, Cambridge, MA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-system rheumatic disease with widely differing clinical manifestations and outcomes. Treatment is generally immunosuppressive, with no available…
Abstract Number: 710 • 2014 ACR/ARHP Annual Meeting
Splenectomy in Systemic LUPUS Erythematosus and AUTOIMMUNE Hematological Diseases. a Comparative Analysis
Luis J. Jara¹, Nahim Barron², Jesús Arenas-Osuna³, Arturo Vélazquez-García⁴, Arturo González-Zúñiga⁴, Miguel A Saavedra⁵ and Pilar Cruz-Domínguez⁶, ¹Direction of Education and Research, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, ²General Surgery, Hospital de Especialidades Centro Médico La Raza, México, Mexico, ³Division of Education, Hospital de Especialidades Centro Médico La Raza, Mexico, Mexico, ⁴General Surgery, Hospital de Especialidades Centro Médico La Raza, Mexico, Mexico, ⁵Reumathology, Hospital de Especialidades Centro Médico La Raza, Mexico, Mexico, ⁶Division of Research, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico
Background/Purpose Acute presentation of severe autoinmune thrombocytopenia, and hemolytic anemia in systemic lupus erythematosus (SLE) is associated with high mortality. Splenectomy is the second line…
Abstract Number: 146 • 2014 ACR/ARHP Annual Meeting
Ultrasonographic Evaluation of Joint and Tendon Involvement in Patients with Early Systemic Lupus Erythematosus (SLE) in Comparison with Early Rheumatoid Arthritis (RA)
Takehisa Ogura¹, Ayako Hirata¹, Norihide Hayashi¹, Rie Kujime², Hideki Ito², Sayaka Takenaka², Sumie Nakahashi², Kennosuke Mizushina², Naoko Yamashita², Yuki Fujisawa² and Hideto Kameda³, ¹Department of Rheumatology, Toho Univ, Tokyo, Japan, ²Toho Univ, Tokyo, Japan, ³Div Rheumatol, Dep Intern Med, Toho Univ, Tokyo, Japan
Background/Purpose: Although both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) may lead to the joint deformity, different characteristics such as the absence or the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].